SCHEMBL5641990

SCHEMBL5641990

CC1CCN(C(=O)n2nnc3ccc(N)cc32)CC1

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FAAH O00519 12/20 0.47
MGLL Q99685 12/20 0.47
HPGD P15428 2/20 0.43
RAB9A P51151 2/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5642585 0.85 FAAH (0.48) FAAHMGLLHPGDRAB9AHTT
SCHEMBL5640188 0.85 MGLL (0.49) FAAHMGLLHPGDRAB9AHTT
SCHEMBL5642345 0.82 MGLL (0.55) FAAHMGLLHPGDHTTSMN1; SMN2
SCHEMBL5639724 0.82 FAAH (0.45) FAAHMGLLHPGDRAB9AHTT
SCHEMBL5641596 0.82 FAAH (0.67) FAAHMGLL
SCHEMBL5643132 0.81 ALDH1A1 (0.51) FAAHMGLLHPGDRAB9AHTT
SCHEMBL5640431 0.80 FAAH (0.51) FAAHMGLLHPGD
SCHEMBL5967969 0.79 MGLL (0.46) FAAHMGLLHPGDRAB9AHTT
SCHEMBL3024500 0.79 MGLL (0.48) FAAHMGLLHPGDRAB9AHTT
SCHEMBL5644355 0.78 HPGD (0.47) FAAHMGLLHPGDRAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208504-B2 Bicyclic inhibitors of hormone sensitive lipase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-04-24 US disclosed
US-7208504-B2 Bicyclic inhibitors of hormone sensitive lipase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-04-24 US disclosed
US-7208504-B2 Bicyclic inhibitors of hormone sensitive lipase SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-04-24 US disclosed
EP-1554259-B1 NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE SANOFI AVENTIS DEUTSCHLAND (DE) 2006-12-27 EP disclosed
EP-1554259-A1 NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE Aventis Pharma Deutschland GmbH (DE) 2005-07-20 EP disclosed
US-20040127484-A1 Novel bicyclic inhibitors of hormone sensitive lipase AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-07-01 US disclosed
WO-2004035550-A1 NOVEL BICYCLIC INHIBITORS OF HORMONE SENSITIVE LIPASE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127484-A1 Novel bicyclic inhibitors of hormone sensitive lipase LIPE, PNLIP, CEL FAAH 144/4885MGLL 20/4885HPGD 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.